Thyroid Eye Disease

Teprotumumab shows promise in treating dysthyroid optic neuropathy

Teprotumumab has demonstrated significant effectiveness in treating dysthyroid optic neuropathy (DON) in patients with active thyroid eye disease (TED), according to a study. The study, which reviewed 10 observational studies and case reports, supplemented by 2 cases from the authors' clinical practice, found that teprotumumab led to substantial improvements in...